After some earlier data sparked questions from analysts, Avidity Biosciences has released more data for its RNA-based ...
New Analyses Related to Aficamten Expand on its Metabolism Pathways,Treatment Effect Associated with Combination Therapy with Disopyramide<br ...
Protalix saw record revenue growth in 2024, driven by increased sales to Chiesi, Pfizer, and Brazil. The company aims to start a Phase 2 trial for PRX-115 in 2025.
Company to host conference call and webcast today at 8:30 a.m. EDT CARMIEL, Israel, March 17, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: ...
Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite ...
Protalix BioTherapeutics, Inc. , a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® ...
Clinical research agreements (CRAs) and developing a regulatory strategy—particularly in connection with the Food and Drug Administration ...
New Evrysdi five-year data from the SUNFISH study showed continued stabilisation of motor function in a broad population of ind ...
Pharmaceutical Technology on MSN18h
EC approves Bristol Myers Squibb’s follicular lymphoma CAR T therapyThe European Commission (EC) has granted expanded approval to Bristol Myers Squibb’s (BMS) cluster of differentiation 19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback